Cheetah Medical's Noninvasive Hemodynamic Monitoring Technology Found to be a Highly Accurate and Promising Tool in Patients With Pulmonary Hypertension

University of Chicago Researchers Find That BIOREACTANCE(R) Technology Provides Superior Accuracy for Monitoring Hemodynamics in Patients Suffering From Pulmonary Hypertension, Suggesting Pivotal Roles in Disease Management and in Research

TEL AVIV, Israel and PORTLAND, Oregon, May 18, 2011 - Results from a study validating Cheetah Medical's noninvasive
NICOM(R) system specifically for use in patients with pulmonary hypertension
were presented Wednesday, May 18th, at the 2011 American Thoracic Society
Annual Meeting in Denver.

Pulmonary hypertension (PH) is a life threatening condition
that affects the heart and lungs. The cause is gradual narrowing of the
lung's arteries which severely impedes blood to flow normally from the heart
through the lungs. This means the heart has to work harder than normal to
push the blood through the lungs. Over time, the heart weakens and cannot
keep up so that blood flow decreases. Eventually, the heart becomes so weak
that it can't pump enough blood to meet the demands of the body, even at
rest, which leads to the debilitating symptoms of heart failure such as
shortness of breath at rest or during minimal activity (for example, climbing
two flights of stairs), tiredness, swelling of the legs and stomach, and
palpitations (abnormal heartbeats).

Clinicians have been seeking better ways to monitor disease
progression in order to refine treatment. However traditional methods to
asses patients' hemodynamic parameters, and most notably patients' cardiac
output (CO), are highly invasive and thus suboptimal for routine serial
assessment of PH.

In this study, the Cheetah Medical NICOM(R) Noninvasive
Cardiac Output & Hemodynamic Monitoring System was used to monitor the
hemodynamic performance of 25 pulmonary hypertension patients. University of
Chicago researchers compared the results obtained with NICOM to those
obtained with two gold-standard methods which are also invasive, the
pulmonary artery catheter, also known as Swan-Ganz catheter, and the Fick
method. The NICOM system provided equally accurate and precise measurements
to the standard methods, but was completely non-invasive.

Stuart Rich, MD, Professor of Medicine at the University of
Chicago and the study's Principle Investigator, said: "Survival in patients
with pulmonary hypertension is closely linked to their cardiac output.
However, because cardiac output measurements have required invasive cardiac
catheterization, patients do not have this measured often. With the
validation of a simple noninvasive technique to measure cardiac output in
these patients, physicians should now be able to evaluate their patients'
status frequently, and better judge the efficacy of their treatments."

Researchers hope that these findings will encourage use of CO
monitoring not only into routine clinical practice to provide objective means
of tracking changes in disease status and response to therapy, but will also
pave the way to explore the utility of this technique in clinical trials as
an early screening tool for differentiating effective versus non-effective
treatments for PH.

About Cheetah Medical

Cheetah Medical's NICOM(R) Noninvasive Cardiac Output and
Hemodynamic Monitoring System uses the company's proprietary BIOREACTANCE(R)
Technology to deliver continuous, accurate, noninvasive cardiac output (CO)
and other vital hemodynamic monitoring parameters, useful for fluid
management and drug titration. The system is US FDA cleared and CE Marked,
and since its commercial launch in 2008 has been adopted by a growing number
of clinicians worldwide. Cheetah Medical headquarters is located in Tel-Aviv,
Israel and its United States headquarters is located in Portland, Oregon. For
more information, visit our website at www.cheetah-medical.com.

    For More Information Contact:
    Yoav Avidor, MD
    Chief Executive Officer
    Cheetah Medical Inc.
    yoav@cheetah-medical.com
    Telephone: +972-3-644-0288

.